TY - JOUR
T1 - Treatment and Outcomes of Primary Pericardial Mesothelioma
T2 - A Contemporary Review of 103 Published Cases
AU - McGehee, Elizabeth
AU - Gerber, David E
AU - Reisch, Joan S
AU - Dowell, Jonathan E
N1 - Funding Information:
Supported in part by a National Cancer Institute Midcareer Investigator Award in Patient-Oriented Research ( K24 CA201543-01 ) (to D.E.G.) and by the National Center for Advancing Translational Sciences of the National Institutes of Health under award UL1TR001105 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using the terms “primary pericardial mesothelioma,” “pericardial mesothelioma,” and “malignant pericardial mesothelioma.” We identified 6 case series and 84 case reports for a total of 103 PPM cases published from 2000 through 2016. The median age at diagnosis was 55 years, and the median overall survival was 6 months. In univariate analyses of clinical characteristics including gender, asbestos exposure, tobacco use, prior radiation exposure, histologic subtype, and metastasis and/or mediastinal spread, only the presence of metastasis and/or mediastinal spread was a significant predictor of decreased survival (P = .015). Surgery did not provide a statistically significant survival benefit (P = .12). A survival benefit was noted in those who received chemotherapy (median survival, 13 months vs. 0.5 months, P = .002), specifically chemotherapy with a platinum agent with or without pemetrexed. In multivariate analysis, only the receipt of chemotherapy was associated with improved survival. PPM remains a rare and poorly understood malignancy with unclear etiology and a poor prognosis. In this retrospective systematic review, a survival benefit was seen in patients who received chemotherapy.
AB - Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using the terms “primary pericardial mesothelioma,” “pericardial mesothelioma,” and “malignant pericardial mesothelioma.” We identified 6 case series and 84 case reports for a total of 103 PPM cases published from 2000 through 2016. The median age at diagnosis was 55 years, and the median overall survival was 6 months. In univariate analyses of clinical characteristics including gender, asbestos exposure, tobacco use, prior radiation exposure, histologic subtype, and metastasis and/or mediastinal spread, only the presence of metastasis and/or mediastinal spread was a significant predictor of decreased survival (P = .015). Surgery did not provide a statistically significant survival benefit (P = .12). A survival benefit was noted in those who received chemotherapy (median survival, 13 months vs. 0.5 months, P = .002), specifically chemotherapy with a platinum agent with or without pemetrexed. In multivariate analysis, only the receipt of chemotherapy was associated with improved survival. PPM remains a rare and poorly understood malignancy with unclear etiology and a poor prognosis. In this retrospective systematic review, a survival benefit was seen in patients who received chemotherapy.
KW - Asbestos
KW - Clinical
KW - Malignancy
KW - Pericardium
KW - Retrospective
UR - http://www.scopus.com/inward/record.url?scp=85059036927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059036927&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2018.11.008
DO - 10.1016/j.cllc.2018.11.008
M3 - Review article
C2 - 30594459
AN - SCOPUS:85059036927
SN - 1525-7304
VL - 20
SP - e152-e157
JO - Clinical lung cancer
JF - Clinical lung cancer
IS - 2
ER -